News – Dec 08, 2017

A successful and valuable RSV Vaccines for the World Conference

The annual RSV Vaccines for the World Conference was held this year in Malaga Spain, from Nov 29th to Dec 1st. The conference was organised by ReSViNET, the RSV network managed and operated by Julius Clinical and the University Medical Center Utrecht.

Almost 300 participants from 38 countries and 5 continents attended the conference. The attendees covered various backgrounds such as Researchers, physicians, pharmaceutical companies, WHO, BMGF, EMA, CDC, NIH, NSIAID and PATH.

Thanks to the Bill & Melinda Gates Foundation and PATH, we were able to give 57 travel grants: 55% for participants from Low & Middle income countries and 45% for Young Researchers. We had more than 90 posters covering the research categories: Basic science and translational studies, Vaccines, Clinical studies and trials and Epidemiology and Modeling.

Scientific program covered the most important topics of this time: 1) RSV burden and mortality, 2) RSV anatomy and Antibodies, 3) Vulnerable Populations, 4) Surveillance, 5) Current status on vaccine development, 6) Correlates of protection and 7) Long-term sequelae and follow-up.

We thank all the members of ReSViNET, the organising committee and the Scientific Advisory Committee for their vital contribution and also the sponsors for supporting the conference.